Effect of dapagliflozin as fourth drug in type ii diabetes mellitus patients with poorly controlled glycemic status on triple drug therapy

Abstract

Background: The worldwide pandemic, diabetes is managed by keeping the patient's glycemic index stable. The first-line treatment for diabetes is metformin; however, when metformin is insufficient, people need to take additional oral hypoglycemic agents (OHAs). A third OHA might be introduced if dual therapy doesn't work. Insulin is usually advised if triple therapy proves to be futile as well. Some people, though, reject insulin and would rather use a different OHA. Proposed as a fourth add-on medication, dapagliflozin's effectiveness requires additional clinical research.